CDTX - Cidara Therapeutics, Inc.

QQQ $ 620.18 $ 0.00 (0 %)

DIA $ 473.96 $ 0.00 (0 %)

SPY $ 679.54 $ 0.00 (0 %)

TLT $ 89.44 $ 0.00 (0 %)

GLD $ 380.61 $ 0.00 (0 %)

Previous Close

$ 103.79

Open

$ 103.24

Bid

$ 103.85 x 4

Ask

$ 105.90 x 4

Day's Range

-- - --

52 Week Range

$ 12.89 - $ 121.21

Volume

849,196

Average Volume

Market Cap

3.26B

Beta (5Y Monthly)

$ 1.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-07-2025	06-30-2025	10-Q
3	05-08-2025	03-31-2025	10-Q
4	03-06-2025	01-01-1970	10-K
5	11-07-2024	09-30-2024	10-Q
6	08-13-2024	06-30-2024	10-Q
7	05-15-2024	03-31-2024	10-Q
8	04-22-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-23-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	08-09-2022	06-30-2022	10-Q
15	05-11-2022	03-31-2022	10-Q
16	03-07-2022	12-31-2021	10-K
17	11-10-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-13-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-13-2020	06-30-2020	10-Q
23	05-13-2020	03-31-2020	10-Q
24	03-04-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	02-28-2019	12-31-2018	10-K
29	11-08-2018	09-30-2018	10-Q
30	08-09-2018	06-30-2018	10-Q
31	05-10-2018	03-31-2018	10-Q
32	02-27-2018	12-31-2017	10-K
33	11-08-2017	09-30-2017	10-Q
34	08-09-2017	06-30-2017	10-Q
35	05-10-2017	03-31-2017	10-Q
36	03-15-2017	12-31-2016	10-K
37	11-10-2016	09-30-2016	10-Q
38	08-11-2016	06-30-2016	10-Q
39	05-12-2016	03-31-2016	10-Q
40	03-18-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

RBC Capital Maintains Outperform on Cidara...
11/07/2025 18:48:28

RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:CDTX) with a Outperform and raises the price target...

Needham Maintains Buy on Cidara Therapeuti...
11/07/2025 10:12:55

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $100...

UPDATE: Cidara Therapeutics Q3 Adj. EPS $(...
11/06/2025 22:55:34

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...

Cidara Therapeutics Q3 EPS $(3.10) Misses ...
11/06/2025 21:25:48

Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

janus-henderson-avidity-biosciences-bridgebio-pharma-and-other-big-stocks-moving-higher-on-monday

Janus Henderson, Avidity Biosciences, Brid...
10/27/2025 14:21:30

Cidara Therapeutics Presents Data On CD38...
10/23/2025 12:03:47

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

HC Wainwright & Co. Reiterates Buy on Cida...
10/21/2025 16:28:56

HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $150 price ta...

Cidara Therapeutics Releases New Phase 2b ...
10/21/2025 12:10:33

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-...

Morgan Stanley Initiates Coverage On Cidar...
10/16/2025 13:07:28

Morgan Stanley analyst Maxwell Skor initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and ann...

cidara-therapeutics-analyst-says-lead-influenza-candidate-is-strategically-attractive

Cidara Therapeutics Analyst Says Lead Infl...
10/10/2025 18:11:11

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's...

cidara-therapeutics-surges-ahead-of-eswi-2025-presentation-and-jp-morgan-coverage

Cidara Therapeutics Surges Ahead of ESWI 2...
10/10/2025 14:55:59

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement ...

Cidara Therapeutics To Present CD388 NAVIG...
10/10/2025 12:14:57

JP Morgan Initiates Coverage On Cidara The...
10/10/2025 11:32:13

JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and announces...

WBB Securities Maintains Strong Buy on Cid...
10/09/2025 18:33:40

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

HC Wainwright & Co. Maintains Buy on Cidar...
10/09/2025 14:50:58

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target ...

FDA Grants Breakthrough Therapy Designatio...
10/09/2025 12:02:37

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

cidara-shares-are-trading-higher-friday-whats-going-on

Cidara Shares Are Trading Higher Friday: W...
10/03/2025 16:53:54

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic i...

JMP Securities Maintains Market Outperform...
10/03/2025 12:07:49

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the pric...

Cidara Secures Up To $339M BARDA Award To ...
10/02/2025 20:06:30

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...